This application is related to HES 2005-IP-016905U2, aplication Ser. No. 11/117,959 filed on the same day herewith.
The present invention relates to acidic treatment fluids used in industrial and oil field operations, and more particularly, to acidic treatment fluids comprising gelling agents that comprise scleroglucan and/or diutan, and their use in industrial and oil field operations. As used herein, the term “treatment fluid” refers to any fluid that may be used in a subterranean application in conjunction with a desired function and/or for a desired purpose. The term “treatment fluid” does not imply any particular action by the fluid or any component thereof.
Acidizing and fracturing procedures using acidic treatment fluids are commonly carried out in subterranean well formations to accomplish a number of purposes including, but not limited to, to facilitate the recovery of desirable hydrocarbons from the formation. One commonly used aqueous acidic treatment fluid comprises hydrochloric acid. Other commonly used acids for acidic treatment fluids include: hydrofluoric acid, acetic acid, formic acid, citric acid, ethylene diamine tetra acetic acid (“EDTA”), glycolic acid, sulfamic acid, and derivatives or combinations thereof.
Acidic treatment fluids are used in various subterranean operations. For example, formation acidizing or “acidizing” is a well known method for increasing the flow of desirable hydrocarbons from a subterranean formation. In a matrix acidizing procedure, an aqueous acidic treatment fluid is introduced into a subterranean formation via a well bore therein under pressure so that the acidic treatment fluid flows into the pore spaces of the formation and reacts with the acid-soluble materials therein. As a result, the pore spaces of that portion of the formation are enlarged, and consequently, the permeability of the formation should increase. The flow of hydrocarbons from the formation is therefore increased because of the increase in formation conductivity caused, inter alia, by dissolution of the formation material. In fracture acidizing procedures, one or more fractures are produced in the formations and an acidic treatment fluid is introduced into the fracture(s) to etch flow channels therein. Acidic treatment fluids also may be used to clean out well bores to facilitate the flow of desirable hydrocarbons. Other acidic treatment fluids may be used in diversion processes, and well bore clean-out processes. A specific example is filter cake removal.
To increase the viscosity of an aqueous acid treatment fluid, a suitable gelling agent may be included in the treatment fluid (often referred to as “gelling” the fluid). Gelling an aqueous acidic treatment fluid may be useful to prevent the acid from becoming prematurely spent and inactive. Additionally, gelling an aqueous acidic treatment fluid may enable the development of wider fractures so that live acid may be forced further into the formation from the well bore. Gelling the acidic treatment fluid may delay the interaction of the acid with an acid soluble component in the well bore or the formation. Moreover, gelling an aqueous acidic treatment fluid may permit better fluid loss control of the fluid.
Acidic treatment fluids used in subterranean operations are predominantly water-based fluids that comprise gelling agents that may increase their viscosities, inter alia, to provide viscosity to control the rate of spending of the acid. These gelling agents are usually biopolymers or synthetic polymers that, when hydrated and at a sufficient concentration, are capable of forming a more viscous fluid. Common gelling agents include polysaccharides (such as xanthan), synthetic polymers (such as polyacrylamide), and surfactant gel systems. Acidic treatment fluids comprising xanthan generally have sufficient viscosity for lower temperature operations. At elevated temperatures (e.g., those above about 120° F. to about 150° F.), however, the viscosity of such xanthan treatment fluids are diminished. Consequently, xanthan may not be a suitable gelling agent for acidic treatment fluids when those fluids are used in well bores that comprise elevated temperatures. Other gelling agents such as synthetic gelling agents (e.g., polyacrylamides) have been used, but they are often difficult to disperse and usually require considerable mixing or agitation to develop full viscosity. Additionally, most conventional gelling agents, including guar and some synthetic polymers, may form acid insoluble residues. Moreover, surfactant gel systems can be expensive, and are often sensitive to impurities. Also, surfactant gel systems often require hydrocarbon breakers.
The present invention relates to acidic treatment fluids used in industrial and oil field operations, and more particularly, to acidic treatment fluids comprising gelling agents that comprise scleroglucan and/or diutan, and their use in industrial and oil field operations.
In one embodiment, the present invention provides a method comprising: providing an acidic treatment fluid that comprises a gelling agent that comprises an aqueous base fluid, an acid, and a gelling agent that comprises scleroglucan and/or diutan; and introducing the acidic treatment fluid into a subterranean formation.
In another embodiment, the present invention provides a method of acidizing a portion of a subterranean formation comprising: providing an acidic treatment fluid that comprises a gelling agent that comprises an aqueous base fluid, an acid, and a gelling agent that comprises scleroglucan and/or diutan; contacting a portion of the subterranean formation with the acidic treatment fluid; and allowing the acidic treatment fluid to interact with a component of the subterranean formation so that the component is dissolved.
In another embodiment, the present invention provides a method of producing hydrocarbons from a subterranean formation that comprises: introducing an acidic treatment fluid comprising an aqueous base fluid, an acid, and a gelling agent that comprises scleroglucan and/or diutan into the subterranean formation; and producing hydrocarbons from the formation.
The features and advantages of the present invention will be readily apparent to those skilled in the art upon a reading of the description of the preferred embodiments that follows.
These drawings illustrate certain aspects of some of the embodiments of the present invention, and should not be used to limit or define the invention.
The present invention relates to acidic treatment fluids used in industrial and oil field operations, and more particularly, to acidic treatment fluids comprising gelling agents that comprise scleroglucan and/or diutan, and their use in industrial and oil field operations. Such operations may involve the removal of scale, fracture acidizing, matrix acidizing, diversion, filter cake removal, or pill removal.
In certain embodiments, the present invention provides fluids and methods that are especially suitable for use in well bores comprising a borehole temperature (“BHT”) of up to about 500° F. A preferred temperature range is a treating temperature below about 250° F. One should note that the ability of the acidic treatment fluids of the present invention to maintain a degree of viscosity at such elevated temperatures may be affected by the time a particular fluid is exposed to such temperatures. For example, in some fracture acidizing applications, there may be a considerable fracture cool-down, which may enable utilization of an acidic treatment fluid of the present invention at BHT above the temperature limit at which the fluid demonstrates viscosity. One of the many advantages of the gelling agents of the present invention is that they typically do not leave undesirable residues in the formation once the fluid has been broken. Another advantage is that the gelling agents are environmentally acceptable in some sensitive environments (such as the North Sea). Additionally, the gelling agents of the present invention may present a cost savings over some conventional gelling agents (like many surfactant-based gelling agents) for acidic treatment fluid applications. The acidic treatment fluids of the present invention may be useful in a wide variety of subterranean treatment operations in which acidic treatment fluids may be suitable.
The acidic treatment fluids of the present invention generally comprise an aqueous base fluid, an acid, and a gelling agent of the present invention that comprises scleroglucan and/or diutan. When used in diversion applications, the treatment fluid may or may not comprise an acid. One of ordinary skill in the art with the benefit of this disclosure will be able to determine whether an acid is appropriate. Generally speaking, the fluids of the present invention have a pH of less than about 4. In preferred embodiments comprising hydrochloric acid, the treatment fluids may have a pH of about 1 or less. In embodiments comprising an organic acid, the treatment fluids may have a pH of about 1 to about 4.
The aqueous base fluids of the treatment fluids of the present invention generally comprise fresh water, salt water, or a brine (e.g., a saturated salt water). Other water sources may be used, including those comprising divalent or trivalent cations, e.g., magnesium, calcium, zinc, or iron. Monovalent brines are preferred and, where used, may be of any weight. One skilled in the art will readily recognize that an aqueous base fluid containing a high level of multi-valent ions should be tested for compatibility prior to use. Salts optionally may be added to the water source, inter alia, to produce a treatment fluid having a desired density or other characteristics. One of ordinary skill in the art with the benefit of this disclosure will recognize the particular type of salt appropriate for particular application, given considerations such as protection of the formation, the presence or absence of reactive clays in the formation adjacent to the well bore, compatibility with the other acidic treatment fluid additives, and the factors affecting wellhead control. A wide variety of salts may be suitable. Examples of suitable salts include, inter alia, potassium chloride, sodium bromide, ammonium chloride, cesium formate, potassium formate, sodium formate, sodium nitrate, calcium bromide, zinc bromide, and sodium chloride. A preferred aqueous base fluid is a 5% ammonium chloride brine with hydrofluoric acid or an organic acid. An artisan of ordinary skill with the benefit of this disclosure will recognize the appropriate concentration of a particular salt to achieve a desired density given factors such as the environmental regulations that may pertain. Also, the composition of the water used also will dictate whether and what type of salt is appropriate. The amount of the base fluid in an acidic treatment fluid of the present invention will vary depending on the purpose of the fluid, the formation characteristics, and whether the fluid will be foamed.
Suitable acids for inclusion in the treatment fluids of the present invention include any acid suitable for use in a subterranean application. Examples include hydrochloric acid, hydrofluoric acid, acetic acid, formic acid, citric acid, ethylene diamine tetra acetic acid (“EDTA”), glycolic acid, sulfamic acid, and derivatives or a combination thereof. Hydrochloric acid, acetic acid, or formic acid may be preferred in certain applications. One should note that the choice of aqueous base fluid and acid should be chosen vis-à-vis the other so that the proper synergistic effect is achieved. The concentration and type of acid selected may be based upon the function of the acid (e.g., scale removal, fracture acidizing, matrix acidizing, removal of fluid loss filter cakes and pills, and the like) and the mineralogy of the formation. It is well known that certain concentrations of acids will form precipitates upon spending. See Gdanski, R. D.: “Kinetics of the Tertiary Reaction of HF on Alumino-Silicates”, SPE 31076 presented at the SPE Formation Damage Symposium, Lafayette, La., Feb. 14-15, 1996. Such tendency to form precipitates should be taken into consideration when choosing an acid. A precipitation control additive (e.g., aluminum chloride) may be desirable to include as well depending on the acid and the formation.
The gelling agents of the present invention may comprise scleroglucan and/or diutan. The gelling agent may be present in an acidic treatment fluid of the present invention in an amount of from about 10 lb/Mgal to about 200 lb/Mgal. Generally speaking, an acidic treatment fluid containing an organic acid may require less of a gelling agent of the present invention than an acidic treatment fluid containing hydrochloric acid.
As noted in the text B
As noted in the text B
In some embodiments, the gelling agents may be at least partially crosslinked through a crosslinking reaction comprising a suitable crosslinking agent. Suitable crosslinking agents include zirconium-based crosslinking agents, chrome-based crosslinking agents, and iron-based crosslinking agents. Crosslinking the gelling agent may be desirable where it is desirable to make a certain acidic treatment fluid more viscous. One of ordinary skill in the art with the benefit of this disclosure will recognize when such crosslinkers are appropriate and what particular crosslinker will be most suitable. Things to take into consideration when choosing a suitable crosslinking agent include the pH range of the fluid, activity of the crosslinking agent, the desired viscosity of the treatment fluid, the temperature sensitivity of the crosslinking agent, and the sheer sensitivity of the fluid in the environment. It should be noted that suitable viscosities could be obtained for acidic treatment fluids that comprise gelling agents that comprise diutan without using crosslinkers. Typically, a crosslinking agent may be included in an amount of from about 0.01 lb/Mgal to about 15 lb/Mgal.
Typical cross-linking agents are transitional metals and/or transition metal complexes such as iron, titanium, chromium and zirconium including reaction products of organic acids including polyfunctional acids including dicarboxylic acids, hydroxy-carboxylic acids, amine-carboxylic acids (including for example acetic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, maleic acid, fumaric acid, lactic acid, aspartic acid, malic acid, mandelic acid, citric acid, and the like). Particularly useful are the hydroxy-carboxylic acids such as lactic, maleic and citric acids. Also useful are the complexes formed with these compounds and ammonia alkyli metals, including methyl amine, propyl amine, diethylamine, triethylene tetramine, isopropyl amine, and the like; and hydroxylamines such as triethanolamine, diethanol amine, and the like. Typical compounds include ferric chloride, titanium lactate, titanium malate, titanium citrate, zirconium lactate, zirconium oxychloride, zirconium hydroxychloride, zirconium citrate, zirconium complex of hydroxyethyl glycine, ammonium zirconium fluoride, zirconium 2-ethylhexanoate, zirconium acetate, zirconium neodecanoate, zirconium acetylacetonate, tetrakis(triethanolamine)zirconate, zirconium carbonate, ammonium zirconium carbonate, zirconyl ammonium carbonate, zirconium lactate, titanium acetylacetonate, titanium ethylacetoacetate, titanium citrate, titanium triethanolamine, ammonium titanium lactate, aluminum citrate, chromium citrate, chromium acetate, chromium propionate, chromium malonate, zirconium malate, ammonium, sodium zirconium lactate, zirconium lactate in combination with isopropylamine or triethanolamine, mixtures thereof and the like. Also useful is the use of crosslinking retarders include tartaric acid, sodium glucoheptonate, glucono-delta lactone, sodium lignosulfonate, combinations there of, and the like.
In certain embodiments, the acidic treatment fluids of the present invention also may comprise suitable: hydrate inhibitor, corrosion inhibitors, pH control additives, surfactants, breakers, fluid loss control additives, scale inhibitors, asphaltene inhibitors, paraffin inhibitors, salts, foamers, defoamers, emulsifiers, demulsifiers, iron control agents, solvents, mutual solvents, particulate diverters, gas phase, carbon dioxide, nitrogen, other biopolymers, synthetic polymers, friction reducers combinations thereof, or the like. The acidic treatment fluids of the present invention also may include other additives that may be suitable for a given application.
In alternative embodiments, the acidic treatment fluids of the present invention may be foamed. In such embodiments, the acidic treatment fluids also comprise a gas, and a foaming agent. While various gases can be utilized for foaming the acidic treatment fluids of this invention, nitrogen, carbon dioxide, and mixtures thereof are preferred. In examples of such embodiments, the gas may be present in an acidic treatment fluid in an amount in the range of from about 5% to about 95% by volume of the treatment fluid, and more preferably in the range of from about 20% to about 80%. The amount of gas to incorporate into the fluid may be affected by factors including the viscosity of the fluid and welihead pressures involved in a particular application. Examples of preferred foaming agents that can be utilized to foam and stabilize the acidic treatment fluids of this invention include, but are not limited to, alkylamidobetaines such as cocoamidopropyl betaine, aipha-olefin sulfonate, trimethyltallowammonium chloride, C8 to C22 alkylethoxylate sulfate and trimethylcocoammonium chloride. Cocoamidopropyl betaine is especially preferred. Other suitable surfactants available from Halliburton Energy Services include: “19N” (cationic surfactant); “G-SPERSE DISPERSANT™” (anionic surfactant); “MORFLO III®” (anionic/nonionic blend surfactant); “HYFLO(R) IV M™” (anionic/nonionic blend surfactant); “PEN-88M™” (nonionic microemulsion surfactant); “HC-2 AGENT™” (amphoteric surfactant); “PEN-88 HT™” (nonionic microemulsion surfactant); “SEM7™” (cationic surfactant); “HOWCO-SUDS™” foaming agent (anionic surfactant); “HOWCO STICKS™” surfactant (anionic surfactant); “A-SPERSE™” (nonionic surfactant); “SSO-21E” surfactant (nonionic microemulsion surfactant); and “SSO-21MW™” (nonionic microemulsion surfactant). Other suitable foaming agents and foam stabilizing agents may be included as well, which will be known to those skilled in the art with the benefit of this disclosure. The foaming agent is generally present in an acidic treatment fluid of the present invention in an amount in the range of from about 0.1% to about 2.0% by weight, more preferably in the amount of from about 0.2% to about 1.0% and most preferably about 0.6%.
Examples of suitable corrosion inhibitors include acetylenic alcohols, Mannich condensation products (such as those formed by reacting an aldehyde, a carbonyl containing compound and a nitrogen containing compound), unsaturated carbonyl compounds, unsaturated ether compounds, formamide, formic acid, formates, other sources of carbonyl, iodides, terpenes, and aromatic hydrocarbons, coffee, tobacco, gelatin, cinnamaldehyde, cinnamaldehyde derivatives, acetylenic alcohols, fluorinated surfactants, quatemary derivatives of heterocyclic nitrogen bases, quaternary derivatives of halomethylated aromatic compounds, formamides, combinations of such compounds used in conjunction with iodine; quaternary ammonium compounds; and combinations thereof. Suitable corrosion inhibitors and intensifiers are available from Halliburton Energy Services and include : “MSA-II™” corrosion inhibitor, “MSA-III” corrosion inhibitor, “HAI-25 E+” environmentally friendly low temp corrosion inhibitor, “HAI-404™” acid corrosion inhibitor, “HAI-50™” Inhibitor, “HAI-60 ™” Corrosion inhibitor, “HAI-62™” acid corrosion inhibitor, “HAI-65™” Corrosion inhibitor, “HAI-72E+™” Corrosion inhibitor, “HAI-75™” High temperature acid inhibitor, “HAI-81M™” Acid corrosion inhibitor, “HAI-85™” Acid corrosion inhibitor, “HAI-85M™” Acid corrosion inhibitor, “HAI- 202 Environmental Corrosion Inhibitor,” “HAI-OS” Corrosion Inhibitor, “HAI-GE” Corrosion Inhibitor, “FDP-S692-03” Corrosion inhibitor for organic acids, “FDP-S656AM-02” and “FDP- S656BW-02” Environmental Corrosion Inhibitor System, “HII-500” Corrosion inhibitor intensifier, “HII-500M” Corrosion inhibitor intensifier, “HII-124” Acid inhibitor intensifier, “HII-124B” Acid inhibitor intensifier, “HII-124C™” Inhibitor intensifier, and “HII-124F™” corrosion inhibitor intensifier. Suitable iron control agents are available from Halliburton Energy Services and include: “FE-2™” Iron sequestering agent, “FE-2A™” Common Law Fe-2A Buffering agent, “FE-3™” Common Law Fe-3 Iron control agent, “FE-3A™” Common Law Fe-3a Iron control agent, “FE-4™” Common Law Fe-4 Iron control agent, “FE-5™” Common Law Fe-5™” Iron control agent, “FE-5A™” Common Law Fe-5a Iron control agent, “FERCHEK®” Ferric iron inhibitor, “FERCHEK (R)” A Reducing agent, and “FERCHEK (R)” SC Iron control process or system. Other suitable iron control agents include those described in U.S. Pat. Nos. 6,315,045, 6,525,011, 6,534,448, and 6,706,668. Examples of corrosion inhibitor activators that may be included include, but are not limited to, cuprous iodide; cuprous chloride; antimony compounds such as antimony oxides, antimony halides, antimony tartrate, antimony citrate, alkali metal salts of antimony tartrate and antimony citrate, alkali metal salts of pyroantimonate and antimony adducts of ethylene glycol; bismuth compounds such as bismuth oxides, bismuth halides, bismuth tartrate, bismuth citrate, alkali metal salts of bismuth tartrate and bismuth citrate; iodine; iodide compounds; formic acid; and mixtures of the foregoing activators such as a mixture of formic acid and potassium iodide. The amount of any corrosion inhibitor to include in an acidic treatment fluid of the present invention will depend on many factors, including but not limited to, the metallurgy the acid will contact, contact time, temperature, etc. Generally, the amount of a corrosion inhibitor to include will range from about 0.1% to about 3% by volume.
Suitable pH control additives, in certain embodiments, may comprise bases, chelating agents, acids, or combinations of chelating agents and acids or bases. A pH control additive may be necessary to maintain the pH of the treatment fluid at a desired level, e.g., to improve the dispersion of the gelling agent in the aqueous base fluid. In some instances, it may be beneficial to maintain the below 3. Suitable pH control additives are those additives that assist in maintaining the pH of an acidic treatment fluid very low, and may include glycolic acids, acetic acids, lactone derivatives, formic acid, carbonic acid, sulfamic acid, and the like.
In some embodiments, the acidic treatment fluids of the present invention may include surfactants, e.g., to improve the compatibility of the acidic treatment fluids with other fluids (like any formation fluids) that may be present in the well bore. Examples of suitable surfactants include ethoxylated nonyl phenol phosphate esters, nonionic surfactants, cationic surfactants, anionic surfactants, alkyl phosphonate surfactants, linear alcohols, nonylphenol compounds, alkyoxylated fatty acids, alkylphenol alkoxylates, ethoxylated amides, ethoxylated alkyl amines, amphoteric surfactants (such as betaines), and mixtures thereof. Suitable surfactants may be used in a liquid or powder form. In an embodiment where liquid surfactants are used, the surfactants are generally present in an amount in the range of from about 0.0 1% to about 5.0% by volume of the acidic treatment fluid. In one embodiment, the liquid surfactants are present in an amount in the range of from about 0.1% to about 2.0% by volume of the acidic treatment fluid. In embodiments where powdered surfactants are used, the surfactants may be present in an amount in the range of from about 0.00 1% to about 0.5% by weight of the acidic treatment fluid. Examples of suitable surfactants are non-emulsifiers commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradenames “LOSURF-259™” solid surfactant, “LOSURF-300™” nonionic surfactant, “LOSURF-357™” nonionic surfactant, and “LOSURF-400™,” surfactant, “LOSURF-2000S™” solid surfactant, and “LOSURF-2000M” solid surfactant, “LOSURLF-357” nonionic surfactant, “LOSURF-400” surfactant, “LOSURF-2000S” surfactant, “LOSURF-259” nonionic non-emulsifier, and “LOSURF-300” nonionic surfactant. Another example of a suitable surfactant is a non-emulsifier commercially available from Halliburton Energy Services, Inc., of Duncan, Oklahoma, under the tradename “NEA-96M™” Surfactant. Other examples of suitable surfactants that are commercially available from Halliburton Energy Services in Duncan, Oklahoma are tradenamed products “SGA-1,” “EFS-1,” “EFS-2,” “EFS-3,” and “EFS-4.”
While typically not required, the acidic treatment fluids of the present invention also may comprise breakers capable of reducing the viscosity of the acidic treatment fluid at a desired time. Examples of such suitable breakers for acidic treatment fluids of the present invention include, but are not limited to, sodium chlorite, hypochlorite, perborate, persulfates, peroxides, including organic peroxides. Other suitable breakers include suitable acids. Preferred examples of suitable breakers for acidic treatment fluids of the present invention that include a gelling agent that comprises diutan include peroxide breakers. Preferred examples include tert-butyl hydroperoxide and tert-amyl hydroperoxide. Sodium persulfate and sodium chlorite are not preferred breakers for acidic treatment fluids of the present invention that include a gelling agent that comprises diutan because optimal degradation generally may not occur within a desirable time period. A breaker may be included in an acidic treatment fluid of the present invention in an amount and form sufficient to achieve the desired viscosity reduction at a desired time. The breaker may be formulated to provide a delayed break, if desired. For example, a suitable breaker may be encapsulated if desired. Suitable encapsulation methods are known to those skilled in the art. One suitable encapsulation method that may be used involves coating the chosen breakers with a material that will degrade when downhole so as to release the breaker when desired. Resins that may be suitable include, but are not limited to, polymeric materials that will degrade when downhole. The terms “degrade,” “degradation,” or “degradable” refer to both the two relatively extreme cases of hydrolytic degradation that the degradable material may undergo, i.e., heterogeneous (or bulk erosion) and homogeneous (or surface erosion), and any stage of degradation in between these two. This degradation can be a result of, inter alia, a chemical or thermal reaction or a reaction induced by radiation. Suitable examples of materials that can undergo such degradation include polysaccharides such as dextran or cellulose; chitins; chitosans; proteins; aliphatic polyesters; poly(lactides); poly(glycolides); poly(ε-caprolactones); poly(hydroxybutyrates); poly(anhydrides); aliphatic polycarbonates; orthoesters, poly(orthoesters); poly(amino acids); poly(ethylene oxides); and polyphosphazenes. If used, a breaker should be included in a composition of the present invention in an amount sufficient to facilitate the desired reduction in viscosity in a viscosifier treatment fluid. For instance, peroxide concentrations that may be used vary from about 0.1 to about 10 gallons of peroxide per 1000 gallons of the acidic treatment fluid. Optionally, the acidic treatment fluid may contain an activator or a retarder, inter alia, to optimize the break rate provided by the breaker.
To facilitate a better understanding of the present invention, the following examples of certain aspects of some embodiments are given. In no way should the following examples be read to limit, or define, the scope of the invention.
Fluid preparation: Acidic treatment fluids comprising scleroglucan were prepared by making a 15% HCl fluid containing 83.5 lb/Mgal of scleroglucan in a Waring blender. The fluid was mixed (hydrated) for 30 minutes. Acidic treatment fluids comprising a diutan gelling agent and a xanthan gelling agent were prepared in a similar manner using 164.9 lb/Mgal and 83.5 lb/Mgal, respectively. A comparative xanthan fluid was prepared using the same process.
Fluid evaluation: The fluids were then evaluated under two different temperature profiles on a Nordman Model 50 viscometer using a modified API2 test. The results are shown in
Therefore, the present invention is well adapted to attain the ends and advantages mentioned as well as those that are inherent therein. While numerous changes may be made by those skilled in the art, such changes are encompassed within the spirit of this invention as defined by the appended claims. The terms in the claims have their plain, ordinary meaning unless otherwise explicitly and clearly defined by the patentee.
Number | Name | Date | Kind |
---|---|---|---|
2238671 | Woodhouse | Apr 1941 | A |
2703316 | Palmer | Mar 1955 | A |
3173484 | Huitt et al. | Mar 1965 | A |
3195635 | Fast | Jul 1965 | A |
3272650 | MacVittie | Sep 1966 | A |
3302719 | Fischer | Feb 1967 | A |
3364995 | Atkins et al. | Jan 1968 | A |
3366178 | Malone et al. | Jan 1968 | A |
3455390 | Gallus | Jul 1969 | A |
3668137 | Gardner | Jun 1972 | A |
3784585 | Schmitt et al. | Jan 1974 | A |
3819525 | Hattenbrun | Jun 1974 | A |
3828854 | Templeton et al. | Aug 1974 | A |
3836465 | Rhudy et al. | Sep 1974 | A |
3868998 | Lybarger et al. | Mar 1975 | A |
3912692 | Casey et al. | Oct 1975 | A |
3948672 | Harnsberger | Apr 1976 | A |
3955993 | Curtice | May 1976 | A |
3960736 | Free et al. | Jun 1976 | A |
3968840 | Tate | Jul 1976 | A |
3986355 | Klaeger | Oct 1976 | A |
3998272 | Maly | Dec 1976 | A |
3998744 | Arnold et al. | Dec 1976 | A |
4010071 | Colegrove | Mar 1977 | A |
4068718 | Cooke, Jr. et al. | Jan 1978 | A |
4169798 | DeMartino | Oct 1979 | A |
4172066 | Zweigle et al. | Oct 1979 | A |
4261421 | Watanabe | Apr 1981 | A |
4265673 | Pace et al. | May 1981 | A |
4299825 | Lee | Nov 1981 | A |
4387769 | Erbstoesser et al. | Jun 1983 | A |
4460052 | Gockel | Jul 1984 | A |
4470915 | Conway | Sep 1984 | A |
4498995 | Gockel | Feb 1985 | A |
4502540 | Byham | Mar 1985 | A |
4506734 | Nolte | Mar 1985 | A |
4521316 | Sikorski | Jun 1985 | A |
4526695 | Erbstoesser et al. | Jul 1985 | A |
4614236 | Watkins et al. | Sep 1986 | A |
4632876 | Laird et al. | Dec 1986 | A |
4694905 | Armbruster | Sep 1987 | A |
4703797 | Djabbarah | Nov 1987 | A |
4715967 | Bellis | Dec 1987 | A |
4716964 | Erbstoesser et al. | Jan 1988 | A |
4767706 | Levesque | Aug 1988 | A |
4772346 | Anderson et al. | Sep 1988 | A |
4784694 | Lemanczyk et al. | Nov 1988 | A |
4785884 | Armbruster | Nov 1988 | A |
4793416 | Mitchell | Dec 1988 | A |
4797262 | Dewitz | Jan 1989 | A |
4809783 | Hollenbeck et al. | Mar 1989 | A |
4817721 | Pober | Apr 1989 | A |
4822500 | Dobson, Jr. et al. | Apr 1989 | A |
4829100 | Murphey et al. | May 1989 | A |
4836940 | Alexander | Jun 1989 | A |
4843118 | Lai et al. | Jun 1989 | A |
4848467 | Cantu et al. | Jul 1989 | A |
4863980 | Cowan et al. | Sep 1989 | A |
4886354 | Welch et al. | Dec 1989 | A |
4887670 | Lord et al. | Dec 1989 | A |
4894231 | Moreau et al. | Jan 1990 | A |
4957165 | Cantu et al. | Sep 1990 | A |
4961466 | Himes et al. | Oct 1990 | A |
4986353 | Clark et al. | Jan 1991 | A |
4986354 | Cantu et al. | Jan 1991 | A |
4986355 | Casad et al. | Jan 1991 | A |
5034139 | Reid et al. | Jul 1991 | A |
5076364 | Hale et al. | Dec 1991 | A |
5082056 | Tackett, Jr. | Jan 1992 | A |
5142023 | Gruber et al. | Aug 1992 | A |
5152781 | Tang et al. | Oct 1992 | A |
5161615 | Hutchins et al. | Nov 1992 | A |
5175278 | Peik et al. | Dec 1992 | A |
5203834 | Hutchins et al. | Apr 1993 | A |
5213446 | Dovan | May 1993 | A |
5216050 | Sinclair | Jun 1993 | A |
5247059 | Gruber et al. | Sep 1993 | A |
5249628 | Surjaatmadja | Oct 1993 | A |
5251697 | Shuler | Oct 1993 | A |
5295542 | Cole et al. | Mar 1994 | A |
5304620 | Holtmyer et al. | Apr 1994 | A |
5314031 | Hale et al. | May 1994 | A |
5325923 | Surjaatmadja et al. | Jul 1994 | A |
5330005 | Card et al. | Jul 1994 | A |
5359026 | Gruber | Oct 1994 | A |
5360068 | Sprunt et al. | Nov 1994 | A |
5363916 | Himes et al. | Nov 1994 | A |
5373901 | Norman et al. | Dec 1994 | A |
5386874 | Laramay et al. | Feb 1995 | A |
5396957 | Surjaatmadja et al. | Mar 1995 | A |
5402846 | Jennings, Jr. et al. | Apr 1995 | A |
5439055 | Card et al. | Aug 1995 | A |
5458197 | Chan | Oct 1995 | A |
5460226 | Lawton et al. | Oct 1995 | A |
5464060 | Hale et al. | Nov 1995 | A |
5475080 | Gruber et al. | Dec 1995 | A |
5484881 | Gruber et al. | Jan 1996 | A |
5487897 | Polson et al. | Jan 1996 | A |
5492177 | Yeh et al. | Feb 1996 | A |
5496557 | Feijen et al. | Mar 1996 | A |
5497830 | Boles et al. | Mar 1996 | A |
5499678 | Surjaatmadja et al. | Mar 1996 | A |
5501276 | Weaver et al. | Mar 1996 | A |
5505787 | Yamaguchi | Apr 1996 | A |
5512071 | Yam et al. | Apr 1996 | A |
5536807 | Gruber et al. | Jul 1996 | A |
5555936 | Pirri et al. | Sep 1996 | A |
5591700 | Harris et al. | Jan 1997 | A |
5594095 | Gruber et al. | Jan 1997 | A |
5602083 | Gabrysch et al. | Feb 1997 | A |
5604186 | Hunt et al. | Feb 1997 | A |
5607905 | Dobson, Jr. et al. | Mar 1997 | A |
5613558 | Dillenbeck | Mar 1997 | A |
5670473 | Scepanski | Sep 1997 | A |
5697440 | Weaver et al. | Dec 1997 | A |
5698322 | Tsai et al. | Dec 1997 | A |
5723416 | Liao | Mar 1998 | A |
5759964 | Shuchart et al. | Jun 1998 | A |
5765642 | Surjaatmadja | Jun 1998 | A |
5783527 | Dobson, Jr. et al. | Jul 1998 | A |
5785747 | Vollmer et al. | Jul 1998 | A |
5791415 | Nguyen et al. | Aug 1998 | A |
5799734 | Norman et al. | Sep 1998 | A |
5833000 | Weaver et al. | Nov 1998 | A |
5849401 | El-Afandi et al. | Dec 1998 | A |
5853048 | Weaver et al. | Dec 1998 | A |
5893416 | Read | Apr 1999 | A |
5908073 | Nguyen et al. | Jun 1999 | A |
5916849 | House | Jun 1999 | A |
5924488 | Nguyen et al. | Jul 1999 | A |
5964291 | Bourne et al. | Oct 1999 | A |
5977030 | House | Nov 1999 | A |
5979557 | Card et al. | Nov 1999 | A |
5996693 | Heathman | Dec 1999 | A |
5996694 | Dewprashad et al. | Dec 1999 | A |
6004400 | Bishop et al. | Dec 1999 | A |
6024170 | McCabe et al. | Feb 2000 | A |
6028113 | Scepanski | Feb 2000 | A |
6047772 | Weaver et al. | Apr 2000 | A |
6100222 | Vollmer et al. | Aug 2000 | A |
6110875 | Tjon-Joe-Pin et al. | Aug 2000 | A |
6114410 | Betzold | Sep 2000 | A |
6123159 | Brookey et al. | Sep 2000 | A |
6123965 | Jacob et al. | Sep 2000 | A |
6131661 | Conner et al. | Oct 2000 | A |
6135987 | Tsai et al. | Oct 2000 | A |
6143698 | Murphey et al. | Nov 2000 | A |
6148917 | Brookey et al. | Nov 2000 | A |
6162766 | Muir et al. | Dec 2000 | A |
6169058 | Le et al. | Jan 2001 | B1 |
6172011 | Card et al. | Jan 2001 | B1 |
6189615 | Sydansk | Feb 2001 | B1 |
6202751 | Chatterji et al. | Mar 2001 | B1 |
6209643 | Nguyen et al. | Apr 2001 | B1 |
6209646 | Reddy et al. | Apr 2001 | B1 |
6214773 | Harris et al. | Apr 2001 | B1 |
6242390 | Mitchell et al. | Jun 2001 | B1 |
6260622 | Blok et al. | Jul 2001 | B1 |
6291013 | Gibson et al. | Sep 2001 | B1 |
6300286 | Dobson, Jr. et al. | Oct 2001 | B1 |
6302209 | Thompson et al. | Oct 2001 | B1 |
6308788 | Patel et al. | Oct 2001 | B1 |
6311773 | Todd et al. | Nov 2001 | B1 |
6315045 | Brezinski | Nov 2001 | B1 |
6323307 | Bigg et al. | Nov 2001 | B1 |
6326458 | Gruber et al. | Dec 2001 | B1 |
6328105 | Betzold | Dec 2001 | B1 |
6330917 | Chatterji et al. | Dec 2001 | B2 |
6357527 | Norman et al. | Mar 2002 | B1 |
6364945 | Chatterji et al. | Apr 2002 | B1 |
6380138 | Ischy et al. | Apr 2002 | B1 |
6387986 | Moradi-Araghi et al. | May 2002 | B1 |
6390195 | Nguyen et al. | May 2002 | B1 |
6394185 | Constien | May 2002 | B1 |
6422314 | Todd et al. | Jul 2002 | B1 |
6422326 | Brookey et al. | Jul 2002 | B1 |
6432155 | Swazey et al. | Aug 2002 | B1 |
6444316 | Reddy et al. | Sep 2002 | B1 |
6454003 | Chang et al. | Sep 2002 | B1 |
6485947 | Rajgarhia et al. | Nov 2002 | B1 |
6488091 | Weaver et al. | Dec 2002 | B1 |
6488763 | Brothers et al. | Dec 2002 | B2 |
6494263 | Todd | Dec 2002 | B2 |
6508305 | Brannon et al. | Jan 2003 | B1 |
6509301 | Vollmer et al. | Jan 2003 | B1 |
6525011 | Brezinski | Feb 2003 | B2 |
6527051 | Reddy et al. | Mar 2003 | B1 |
6534448 | Brezinski | Mar 2003 | B1 |
6547871 | Chatterji et al. | Apr 2003 | B2 |
6554071 | Reddy et al. | Apr 2003 | B1 |
6566310 | Chan | May 2003 | B2 |
6569814 | Brady et al. | May 2003 | B1 |
6578630 | Simpson et al. | Jun 2003 | B2 |
6599863 | Palmer et al. | Jul 2003 | B1 |
6640898 | Lord et al. | Nov 2003 | B2 |
6667279 | Hessert et al. | Dec 2003 | B1 |
6669771 | Tokiwa et al. | Dec 2003 | B2 |
6681856 | Chatterji et al. | Jan 2004 | B1 |
6686328 | Binder | Feb 2004 | B1 |
6691780 | Nguyen et al. | Feb 2004 | B2 |
6702023 | Harris et al. | Mar 2004 | B1 |
6706668 | Brezinski | Mar 2004 | B2 |
6710019 | Sawdon et al. | Mar 2004 | B1 |
6716797 | Brookey | Apr 2004 | B2 |
6737385 | Todd et al. | May 2004 | B2 |
6761218 | Nguyen et al. | Jul 2004 | B2 |
6763888 | Harris et al. | Jul 2004 | B1 |
6764981 | Eoff et al. | Jul 2004 | B1 |
6767869 | DiLullo et al. | Jul 2004 | B2 |
6793018 | Dawson et al. | Sep 2004 | B2 |
6793730 | Reddy et al. | Sep 2004 | B2 |
6806235 | Mueller et al. | Oct 2004 | B1 |
6817414 | Lee | Nov 2004 | B2 |
6818594 | Freeman et al. | Nov 2004 | B1 |
6837309 | Boney et al. | Jan 2005 | B2 |
6840318 | Lee et al. | Jan 2005 | B2 |
6852173 | Banerjee et al. | Feb 2005 | B2 |
6861394 | Ballard et al. | Mar 2005 | B2 |
6877563 | Todd et al. | Apr 2005 | B2 |
6883608 | Parlar et al. | Apr 2005 | B2 |
6886635 | Hossaini et al. | May 2005 | B2 |
6896058 | Munoz, Jr. et al. | May 2005 | B2 |
6904971 | Brothers et al. | Jun 2005 | B2 |
6949491 | Cooke, Jr. | Sep 2005 | B2 |
6959767 | Horton et al. | Nov 2005 | B2 |
6978838 | Parlar et al. | Dec 2005 | B2 |
6981552 | Reddy et al. | Jan 2006 | B2 |
6983801 | Dawson et al. | Jan 2006 | B2 |
6987083 | Phillippi et al. | Jan 2006 | B2 |
6997259 | Nguyen | Feb 2006 | B2 |
7000701 | Todd et al. | Feb 2006 | B2 |
7007752 | Reddy et al. | Mar 2006 | B2 |
7021337 | Todd et al. | Apr 2006 | B2 |
7021383 | Todd et al. | Apr 2006 | B2 |
7032663 | Nguyen | Apr 2006 | B2 |
7036586 | Roddy et al. | May 2006 | B2 |
7036587 | Munoz, Jr. et al. | May 2006 | B2 |
7044220 | Nguyen et al. | May 2006 | B2 |
7044224 | Nguyen | May 2006 | B2 |
7049272 | Sinclair et al. | May 2006 | B2 |
7063151 | Nguyen et al. | Jun 2006 | B2 |
7066258 | Justus et al. | Jun 2006 | B2 |
7066260 | Sullivan et al. | Jun 2006 | B2 |
7069994 | Cooke, Jr. | Jul 2006 | B2 |
7080688 | Todd et al. | Jul 2006 | B2 |
7093664 | Todd et al. | Aug 2006 | B2 |
7096947 | Todd et al. | Aug 2006 | B2 |
7101829 | Guichard et al. | Sep 2006 | B2 |
7131491 | Blauch et al. | Nov 2006 | B2 |
7132389 | Lee | Nov 2006 | B2 |
7140438 | Frost et al. | Nov 2006 | B2 |
7147067 | Getzlaf et al. | Dec 2006 | B2 |
7151077 | Prud'homme et al. | Dec 2006 | B2 |
7153902 | Altes et al. | Dec 2006 | B2 |
7156174 | Roddy et al. | Jan 2007 | B2 |
7159659 | Welton et al. | Jan 2007 | B2 |
7165617 | Lord et al. | Jan 2007 | B2 |
7166560 | Still et al. | Jan 2007 | B2 |
7168489 | Frost et al. | Jan 2007 | B2 |
7172022 | Reddy et al. | Feb 2007 | B2 |
7178596 | Blauch et al. | Feb 2007 | B2 |
7195068 | Todd | Mar 2007 | B2 |
7204312 | Roddy et al. | Apr 2007 | B2 |
7205264 | Boles | Apr 2007 | B2 |
7216705 | Saini et al. | May 2007 | B2 |
7219731 | Sullivan | May 2007 | B2 |
7228904 | Todd et al. | Jun 2007 | B2 |
7256159 | Guichard et al. | Aug 2007 | B2 |
7261156 | Nguyen et al. | Aug 2007 | B2 |
7264051 | Nguyen et al. | Sep 2007 | B2 |
7265079 | Wilbert et al. | Sep 2007 | B2 |
7267170 | Mang et al. | Sep 2007 | B2 |
7276466 | Todd et al. | Oct 2007 | B2 |
7299869 | Kalman | Nov 2007 | B2 |
7299876 | Lord et al. | Nov 2007 | B2 |
7303014 | Reddy et al. | Dec 2007 | B2 |
7306037 | Nguyen et al. | Dec 2007 | B2 |
7322412 | Badalamenti et al. | Jan 2008 | B2 |
7345013 | Fraser | Mar 2008 | B2 |
7353876 | Savery et al. | Apr 2008 | B2 |
7353879 | Todd et al. | Apr 2008 | B2 |
7448450 | Luke et al. | Nov 2008 | B2 |
7497278 | Schriener et al. | Mar 2009 | B2 |
20010016562 | Muir et al. | Aug 2001 | A1 |
20010027880 | Brookey | Oct 2001 | A1 |
20020031525 | Kobzeff et al. | Mar 2002 | A1 |
20020036088 | Todd | Mar 2002 | A1 |
20020092652 | Chatterji et al. | Jul 2002 | A1 |
20020119169 | Angel et al. | Aug 2002 | A1 |
20020125012 | Dawson et al. | Sep 2002 | A1 |
20030054962 | England et al. | Mar 2003 | A1 |
20030060374 | Cooke, Jr. | Mar 2003 | A1 |
20030114314 | Ballard et al. | Jun 2003 | A1 |
20030130133 | Vollmer | Jul 2003 | A1 |
20030147965 | Bassett et al. | Aug 2003 | A1 |
20030166472 | Pursley et al. | Sep 2003 | A1 |
20030188766 | Banerjee et al. | Oct 2003 | A1 |
20030230407 | Vijn et al. | Dec 2003 | A1 |
20030234103 | Lee et al. | Dec 2003 | A1 |
20030236174 | Fu et al. | Dec 2003 | A1 |
20040014606 | Parlar et al. | Jan 2004 | A1 |
20040014607 | Sinclair et al. | Jan 2004 | A1 |
20040023812 | England et al. | Feb 2004 | A1 |
20040040706 | Hossaini et al. | Mar 2004 | A1 |
20040055747 | Lee | Mar 2004 | A1 |
20040070093 | Mathiowitz et al. | Apr 2004 | A1 |
20040094300 | Sullivan et al. | May 2004 | A1 |
20040099416 | Vijn et al. | May 2004 | A1 |
20040106525 | Willbert et al. | Jun 2004 | A1 |
20040129459 | Guichard et al. | Jul 2004 | A1 |
20040138068 | Rimmer et al. | Jul 2004 | A1 |
20040152601 | Still et al. | Aug 2004 | A1 |
20040152602 | Boles | Aug 2004 | A1 |
20040162386 | Altes et al. | Aug 2004 | A1 |
20040170836 | Bond et al. | Sep 2004 | A1 |
20040206498 | Phillippi et al. | Oct 2004 | A1 |
20040214724 | Todd et al. | Oct 2004 | A1 |
20040216876 | Lee | Nov 2004 | A1 |
20040216882 | Horton et al. | Nov 2004 | A1 |
20040231845 | Cooke, Jr. | Nov 2004 | A1 |
20040238169 | Todd et al. | Dec 2004 | A1 |
20050000734 | Getzlaf et al. | Jan 2005 | A1 |
20050028976 | Nguyen | Feb 2005 | A1 |
20050028978 | Parlar et al. | Feb 2005 | A1 |
20050034861 | Saini et al. | Feb 2005 | A1 |
20050059556 | Munoz, Jr., et al. | Mar 2005 | A1 |
20050059557 | Todd et al. | Mar 2005 | A1 |
20050059558 | Blauch et al. | Mar 2005 | A1 |
20050103496 | Todd et al. | May 2005 | A1 |
20050126785 | Todd et al. | Jun 2005 | A1 |
20050130848 | Todd et al. | Jun 2005 | A1 |
20050183741 | Surjaatmadja et al. | Aug 2005 | A1 |
20050205266 | Todd et al. | Sep 2005 | A1 |
20050252659 | Sullivan et al. | Nov 2005 | A1 |
20050261138 | Robb et al. | Nov 2005 | A1 |
20050272613 | Cooke, Jr. | Dec 2005 | A1 |
20050277554 | Blauch et al. | Dec 2005 | A1 |
20060014648 | Milson et al. | Jan 2006 | A1 |
20060016596 | Pauls et al. | Jan 2006 | A1 |
20060032633 | Nguyen | Feb 2006 | A1 |
20060046938 | Harris et al. | Mar 2006 | A1 |
20060048938 | Kalman | Mar 2006 | A1 |
20060054324 | Sullivan et al. | Mar 2006 | A1 |
20060065397 | Nguyen et al. | Mar 2006 | A1 |
20060105917 | Munoz, Jr., et al. | May 2006 | A1 |
20060105918 | Munoz, Jr., et al. | May 2006 | A1 |
20060108150 | Luke et al. | May 2006 | A1 |
20060166836 | Pena et al. | Jul 2006 | A1 |
20060169182 | Todd et al. | Aug 2006 | A1 |
20060169450 | Mang et al. | Aug 2006 | A1 |
20060172891 | Todd et al. | Aug 2006 | A1 |
20060172893 | Todd et al. | Aug 2006 | A1 |
20060172894 | Mang et al. | Aug 2006 | A1 |
20060172895 | Mang et al. | Aug 2006 | A1 |
20060180309 | Welton et al. | Aug 2006 | A1 |
20060180310 | Welton et al. | Aug 2006 | A1 |
20060183646 | Welton et al. | Aug 2006 | A1 |
20060185847 | Saini et al. | Aug 2006 | A1 |
20060185848 | Surjaatmadja et al. | Aug 2006 | A1 |
20060234873 | Ballard | Oct 2006 | A1 |
20060258543 | Saini | Nov 2006 | A1 |
20060258544 | Saini | Nov 2006 | A1 |
20060276345 | Todd et al. | Dec 2006 | A1 |
20060278437 | Guichard et al. | Dec 2006 | A1 |
20060283597 | Schreiner et al. | Dec 2006 | A1 |
20070100029 | Reddy et al. | May 2007 | A1 |
20070235190 | Lord et al. | Oct 2007 | A1 |
20080070810 | Mang | Mar 2008 | A1 |
Number | Date | Country |
---|---|---|
0 146 981 | Nov 1984 | EP |
0 510 762 | Oct 1992 | EP |
0 879 935 | Nov 1998 | EP |
1 413 710 | Apr 2004 | EP |
2 570 753 | Sep 1984 | FR |
2 570 754 | Sep 1984 | FR |
2 570 755 | Sep 1984 | FR |
2 570 756 | Sep 1984 | FR |
2 600 664 | Jun 1986 | FR |
2 354 541 | Mar 2001 | GB |
2 412 389 | Mar 2004 | GB |
2004181820 | Jul 2004 | JP |
WO 9315127 | Aug 1993 | WO |
WO 9407949 | Apr 1994 | WO |
WO 9408078 | Apr 1994 | WO |
WO 9408090 | Apr 1994 | WO |
WO 9509879 | Apr 1995 | WO |
WO 9512741 | May 1995 | WO |
WO 9711845 | Apr 1997 | WO |
WO 9927229 | Jun 1999 | WO |
WO 0057022 | Sep 2000 | WO |
WO 0102698 | Jan 2001 | WO |
WO 0187797 | Nov 2001 | WO |
WO 0194744 | Dec 2001 | WO |
WO 0255843 | Jan 2002 | WO |
WO 0212674 | Feb 2002 | WO |
WO 03027431 | Apr 2003 | WO |
WO 2004007905 | Jan 2004 | WO |
WO 2004037946 | May 2004 | WO |
WO 2004038176 | May 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20060243449 A1 | Nov 2006 | US |